YARW
Yarrow Bioscience IncHealthcare · $184M market cap
Verdict
We can't put a fair value on YARW right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow YARW
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Oct 29, 2026: no open-market purchases and 5 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
Questions about YARW
Are insiders buying YARW?
Since Oct 29, 2026: no open-market purchases and 5 other filings (stock awards, tax withholding and similar).
How can I check YARW's value myself?
Use the free Sticker Price calculator, already filled with YARW's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About Yarrow Bioscience Inc
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Oct 30, 2026. How the Payback Price works